Compass Therapeutics, Inc.

NasdaqCM CMPX

Compass Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Compass Therapeutics, Inc. EBT Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

NasdaqCM: CMPX

Compass Therapeutics, Inc.

CEO	Dr. Thomas J. Schuetz M.D., Ph.D.
IPO Date	April 5, 2021
Location	United States
Headquarters	80 Guest Street
Employees	32
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Pharmaceuticals

Description

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Key trends

Past 5 years